Pearl Therapeutics

Pearl was founded in 2006, with a mission to develop differentiated therapeutics for respiratory disease conditions prevalent worldwide, including chronic obstructive pulmonary disease (COPD). The product candidates currently being developed are based on the simple and widely prescribed metered-dose inhaler (MDI) dosage form. Company scientists have invented a novel cosuspension formulation technology for use with MDIs that enables efficient targeting and distribution of drug to the lungs.

Pearl has an experienced team of inhalation product development experts with proven track record in the development and commercialization of innovative respiratory products. Pearl’s lead product candidates are a fixed-dose combination bronchodilator, PT003 (glycopyrronium and formoterol fumarate), and its monotherapy components, PT001 (glycopyrronium) and PT005 (formoterol fumarate) for the treatment of COPD.